UTRS Stock Overview
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Minerva Surgical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.41 |
| 52 Week High | US$14.00 |
| 52 Week Low | US$0.30 |
| Beta | 0.68 |
| 1 Month Change | -25.45% |
| 3 Month Change | -57.29% |
| 1 Year Change | -91.93% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.77% |
Recent News & Updates
Recent updates
Is There An Opportunity With Minerva Surgical, Inc.'s (NASDAQ:UTRS) 44% Undervaluation?
Aug 11
Minerva downgraded at JPMorgan citing lowered guidance
Aug 10Minerva Surgical, Inc. (NASDAQ:UTRS) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 10Minerva Surgical - Uterine Play For Sale
Nov 02Shareholder Returns
| UTRS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -19.6% | 1.4% | 1.2% |
| 1Y | -91.9% | -0.7% | 24.7% |
Return vs Industry: UTRS underperformed the US Medical Equipment industry which returned -3.7% over the past year.
Return vs Market: UTRS underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| UTRS volatility | |
|---|---|
| UTRS Average Weekly Movement | 18.7% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: UTRS's share price has been volatile over the past 3 months.
Volatility Over Time: UTRS's weekly volatility has decreased from 24% to 19% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 174 | Todd Usen | minervasurgical.com |
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices.
Minerva Surgical, Inc. Fundamentals Summary
| UTRS fundamental statistics | |
|---|---|
| Market cap | US$3.64m |
| Earnings (TTM) | -US$33.45m |
| Revenue (TTM) | US$51.69m |
0.1x
P/S Ratio-0.1x
P/E RatioIs UTRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UTRS income statement (TTM) | |
|---|---|
| Revenue | US$51.69m |
| Cost of Revenue | US$23.69m |
| Gross Profit | US$28.01m |
| Other Expenses | US$61.46m |
| Earnings | -US$33.45m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.77 |
| Gross Margin | 54.18% |
| Net Profit Margin | -64.71% |
| Debt/Equity Ratio | 195.2% |
How did UTRS perform over the long term?
See historical performance and comparison